Product
Ceftolozane/Tazobactam
Aliases
MK-7625A
5 clinical trials
8 indications
Indication
nosocomial pneumoniaIndication
Complicated UTIIndication
PyelonephritisIndication
Complicated Intra-Abdominal InfectionIndication
complicated intra-abdominal infectionsIndication
Pseudomonas aeruginosaIndication
PneumoniaIndication
hematologic malignanciesClinical trial
A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial PneumoniaStatus: Recruiting, Estimated PCD: 2025-09-22
Clinical trial
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including PyelonephritisStatus: Completed, Estimated PCD: 2020-12-03
Clinical trial
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal InfectionStatus: Completed, Estimated PCD: 2020-03-16
Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal InfectionStatus: Completed, Estimated PCD: 2020-10-14
Clinical trial
A Pilot Study of Ceftolozane-Tazobactam in Conjunction With Rapid Molecular Diagnosis for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-05-30